Form 4 for ABUS Arbutus Biopharma Corp

Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001447028-24-000028 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-02-05	2024-02-01	ABUS	Sims Karen	Chief Medical Off	A - Grant	$0.00	+101.0K	129.9K	+349%	$0
D	2024-02-05	2024-02-02	ABUS	Sims Karen	Chief Medical Off	S - Sale	$2.31	-4,358	125.5K	-3%	-$10.1K
D	2024-02-05	2024-02-01	ABUS	Sims Karen	Chief Medical Off	A - Grant	$0.00	+403.9K	403.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2024-02-01	A	A	101,000	$0.00	129,900	D	—	—	(F1) Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
2	Common	Common Shares	2024-02-02	S	D	4,358	$2.31	125,542	D	—	—
3	Derivative	Stock Option (Right to Buy)	2024-02-01	A	A	403,900	$0.00	403,900	D	$2.40 · — to 2034-02-01	403,900 Common Shares	(F3) Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. (F4) This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.